
Combipatch (Estradiol/Norethindrone Acetate Transdermal System)
Estradiol/Norethindrone Acetate Transdermal System
- SKU
- 68968-0514
- Mfr
- Noven Therapeutics, LLC
3.5 d in 1 patch, 1 patch in 1 pouch, 8 pouch in 1 carton
$343.99
Price for one pack
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.
- Strength
- Estradiol .05 mg/d, Norethindrone Acetate .14 mg/d
- Unit of measure
- Per d
- Dosage form
- Patch, Extended Release
- Route
- Transdermal
Pharmacologic class
- Estradiol CongenersChemical structure
- Estrogen Receptor AgonistsMechanism
- EstrogenEstablished class
- Progesterone CongenersChemical structure
- ProgestinEstablished class
- Brand name
- Combipatch (Estradiol/Norethindrone Acetate Transdermal System)
- Generic name
- Estradiol/Norethindrone Acetate Transdermal System
- Manufacturer
- Noven Therapeutics, LLC
- Product NDC (SKU)
- 68968-0514
- Active ingredients
- Estradiol .05 mg/d, Norethindrone Acetate .14 mg/d
- Unit of measure
- Per d
- Dosage form
- Patch, Extended Release
- Route
- Transdermal
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA020870
- Marketed since
- August 7, 1998
- Label revised
- February 21, 2024
| Package NDC | Description |
|---|---|
| 68968-0514-8 | 8 POUCH in 1 CARTON (68968-0514-8) / 1 PATCH in 1 POUCH / 3.5 d in 1 PATCH |
Reading this NDC
68968-0514-8
- 01Labeler code
- Noven Therapeutics, LLC
- 02Product code
- Combipatch (Estradiol/Norethindrone Acetate Transdermal System), patch, extended release
- 03Package code
- 8 pouch in 1 carton (68968-0514-8) / 1 patch in 1 pouch / 3.5 d in 1 patch
Warning: Cardiovascular disorders, breast cancer, endometrial cancer, and probable dementia
Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia ). The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders ).
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See CLINICAL STUDIES and WARNINGS, Probable Dementia and PRECAUTIONS, Geriatric Use ).
Breast Cancer The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer. (See CLINICAL STUDIES and WARNINGS, Malignant Neoplasms, Breast Cancer ). In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.
Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. (See WARNINGS, Malignant Neoplasms, Endometrial Cancer ). Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia ).
The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders ). The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo.
It is unknown whether this finding applies to younger postmenopausal women. (See CLINICAL STUDIES and WARNINGS, Probable Dementia and PRECAUTIONS, Geriatric Use ). In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
Read before you order

Women's health · 2 min read
The combined pill vs the progestogen-only pill
How combined and progestogen-only contraceptive pills differ, who each suits, the side effects and what to do about a missed pill.

Women's health · 2 min read
Menopause hormone therapy (HRT) explained
How HRT relieves hot flushes and other menopause symptoms, why a progestogen is needed, patches vs tablets and the risks in context.

Women's health · 1 min read
Clomiphene for fertility: how ovulation induction works
How clomiphene triggers ovulation, how a treatment cycle is timed and monitored, the chance of twins and the side effects.
More in Women's Health
View all
Brand · Tablet
Activella
Estradiol .5 mg/1, Norethindrone Acetate .1 mg/1
- SKU
- 60846-231
- Mfr
- Amneal Pharmaceuticals LLC
From $30.99Min. 10 packs

Brand · Tablet
Angeliq
Estradiol .5 mg/1, Drospirenone .25 mg/1
- SKU
- 50419-482
- Mfr
- Bayer HealthCare Pharmaceuticals Inc.
From $120.99Min. 3 packs

Generic · Tablet
Clomid
Clomiphene Citrate 50 mg/1
- SKU
- 0713-0885
- Mfr
- Cosette Pharmaceuticals, Inc.
From $224.99Min. 2 packs

Generic · Tablet
Clomid
Clomiphene Citrate 50 mg/1
- SKU
- 50090-6500
- Mfr
- A-S Medication Solutions
From $678.99